The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors

Allison S. Harney, George S. Karagiannis, Jeanine Pignatelli, Bryan D. Smith, Ece Kadioglu, Scott C. Wise, Molly M. Hood, Michael D. Kaufman, Cynthia B. Leary, Wei Ping Lu, Gada Al-Ani, Xiaoming Chen, David R. Entenberg, Maja H. Oktay, Yarong Wang, Lawrence Chun, Michele De Palma, Joan G. Jones, Daniel L. Flynn, John S. Condeelis

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy. Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and protumoral Tie2-expressing macrophages in mouse models of metastatic cancer. Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through reduction of Tie2+ myeloid cell infiltration, antiangiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM). The antitumor effects of rebastinib enhance the efficacy of microtubule inhibiting chemotherapeutic agents, either eribulin or paclitaxel, by reducing tumor volume, metastasis, and improving overall survival. Rebastinib inhibition of angiopoietin/Tie2 signaling impairs multiple pathways in tumor progression mediated by protumoral Tie2+ macrophages, including TMEM-dependent dissemination and angiopoietin/Tie2-dependent angiogenesis. Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients.

Original languageEnglish (US)
Pages (from-to)2486-2501
Number of pages16
JournalMolecular Cancer Therapeutics
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Neuroendocrine Tumors
Macrophages
Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Angiopoietins
Tumor Microenvironment
eribulin
Myeloid Cells
Receptor Protein-Tyrosine Kinases
Paclitaxel
Tumor Burden
Microtubules
Vascular Endothelial Growth Factor A
Phosphotransferases
Radiotherapy
Endothelial Cells
Drug Therapy
Survival
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors. / Harney, Allison S.; Karagiannis, George S.; Pignatelli, Jeanine; Smith, Bryan D.; Kadioglu, Ece; Wise, Scott C.; Hood, Molly M.; Kaufman, Michael D.; Leary, Cynthia B.; Lu, Wei Ping; Al-Ani, Gada; Chen, Xiaoming; Entenberg, David R.; Oktay, Maja H.; Wang, Yarong; Chun, Lawrence; De Palma, Michele; Jones, Joan G.; Flynn, Daniel L.; Condeelis, John S.

In: Molecular Cancer Therapeutics, Vol. 16, No. 11, 01.11.2017, p. 2486-2501.

Research output: Contribution to journalArticle

Harney, AS, Karagiannis, GS, Pignatelli, J, Smith, BD, Kadioglu, E, Wise, SC, Hood, MM, Kaufman, MD, Leary, CB, Lu, WP, Al-Ani, G, Chen, X, Entenberg, DR, Oktay, MH, Wang, Y, Chun, L, De Palma, M, Jones, JG, Flynn, DL & Condeelis, JS 2017, 'The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors', Molecular Cancer Therapeutics, vol. 16, no. 11, pp. 2486-2501. https://doi.org/10.1158/1535-7163.MCT-17-0241
Harney, Allison S. ; Karagiannis, George S. ; Pignatelli, Jeanine ; Smith, Bryan D. ; Kadioglu, Ece ; Wise, Scott C. ; Hood, Molly M. ; Kaufman, Michael D. ; Leary, Cynthia B. ; Lu, Wei Ping ; Al-Ani, Gada ; Chen, Xiaoming ; Entenberg, David R. ; Oktay, Maja H. ; Wang, Yarong ; Chun, Lawrence ; De Palma, Michele ; Jones, Joan G. ; Flynn, Daniel L. ; Condeelis, John S. / The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 11. pp. 2486-2501.
@article{062b6400b0ab4aee86b2c3f378e9a05d,
title = "The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors",
abstract = "Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy. Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and protumoral Tie2-expressing macrophages in mouse models of metastatic cancer. Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through reduction of Tie2+ myeloid cell infiltration, antiangiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM). The antitumor effects of rebastinib enhance the efficacy of microtubule inhibiting chemotherapeutic agents, either eribulin or paclitaxel, by reducing tumor volume, metastasis, and improving overall survival. Rebastinib inhibition of angiopoietin/Tie2 signaling impairs multiple pathways in tumor progression mediated by protumoral Tie2+ macrophages, including TMEM-dependent dissemination and angiopoietin/Tie2-dependent angiogenesis. Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients.",
author = "Harney, {Allison S.} and Karagiannis, {George S.} and Jeanine Pignatelli and Smith, {Bryan D.} and Ece Kadioglu and Wise, {Scott C.} and Hood, {Molly M.} and Kaufman, {Michael D.} and Leary, {Cynthia B.} and Lu, {Wei Ping} and Gada Al-Ani and Xiaoming Chen and Entenberg, {David R.} and Oktay, {Maja H.} and Yarong Wang and Lawrence Chun and {De Palma}, Michele and Jones, {Joan G.} and Flynn, {Daniel L.} and Condeelis, {John S.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0241",
language = "English (US)",
volume = "16",
pages = "2486--2501",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors

AU - Harney, Allison S.

AU - Karagiannis, George S.

AU - Pignatelli, Jeanine

AU - Smith, Bryan D.

AU - Kadioglu, Ece

AU - Wise, Scott C.

AU - Hood, Molly M.

AU - Kaufman, Michael D.

AU - Leary, Cynthia B.

AU - Lu, Wei Ping

AU - Al-Ani, Gada

AU - Chen, Xiaoming

AU - Entenberg, David R.

AU - Oktay, Maja H.

AU - Wang, Yarong

AU - Chun, Lawrence

AU - De Palma, Michele

AU - Jones, Joan G.

AU - Flynn, Daniel L.

AU - Condeelis, John S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy. Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and protumoral Tie2-expressing macrophages in mouse models of metastatic cancer. Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through reduction of Tie2+ myeloid cell infiltration, antiangiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM). The antitumor effects of rebastinib enhance the efficacy of microtubule inhibiting chemotherapeutic agents, either eribulin or paclitaxel, by reducing tumor volume, metastasis, and improving overall survival. Rebastinib inhibition of angiopoietin/Tie2 signaling impairs multiple pathways in tumor progression mediated by protumoral Tie2+ macrophages, including TMEM-dependent dissemination and angiopoietin/Tie2-dependent angiogenesis. Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients.

AB - Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy. Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and protumoral Tie2-expressing macrophages in mouse models of metastatic cancer. Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through reduction of Tie2+ myeloid cell infiltration, antiangiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM). The antitumor effects of rebastinib enhance the efficacy of microtubule inhibiting chemotherapeutic agents, either eribulin or paclitaxel, by reducing tumor volume, metastasis, and improving overall survival. Rebastinib inhibition of angiopoietin/Tie2 signaling impairs multiple pathways in tumor progression mediated by protumoral Tie2+ macrophages, including TMEM-dependent dissemination and angiopoietin/Tie2-dependent angiogenesis. Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85032802840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032802840&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0241

DO - 10.1158/1535-7163.MCT-17-0241

M3 - Article

C2 - 28838996

AN - SCOPUS:85032802840

VL - 16

SP - 2486

EP - 2501

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -